| Developers: | BioPharmaHolding |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
2024: Sales growth of 41%
The Russian aesthetic brand COLLOST, which has been promoting the pharmaceutical company Binnopharm Group since 2022, showed sales growth of 41% in 2024 compared to 2023. Binnopharm Group announced this on February 26, 2025.
Collagen material COLLOST, a Russian development, has been showing high sales dynamics for several years. The expansion of the line and the launch of the product, COLLOST Micro, made it possible to increase the audience and occupy the niche of the departed foreign companies.
The collagen injection product segment, which includes the COLLOST line, grew by 114% in monetary terms in 2024, becoming one of the key drivers of growth in the biorevitalizants and fillers market.
COLLOST is a natural injection collagen that promotes dermal repair by activating collagenogenesis. Biomaterial based on natural collagen promotes tissue regeneration, stimulates the formation of new collagen fibers.
The injection product for February 2025 is available in eight countries of the world, the line includes a ready-made drug (gel) in syringes of various volumes, sterile collagen type I (powder) in a vial, as well as post-treatment spray.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |